Grace Ferguson1, Luke Gilligan1, Caitlyn Keogh1 and Paul H Hartel2-4*
1Department of Forensic Investigation and Analysis, Atlantic Technological University, Ireland
2Sligo University Hospital, Department of Pathology, Ireland
3National University of Ireland, Galway School of Medicine, Department of Pathology, Ireland
4West Virginia University School of Medicine, Department of Medicine, USA
*Corresponding Author: Paul H Hartel, Sligo University Hospital, Department of Pathology, Ireland.
Received: December 09, 2022; Published: December 19, 2022
While serum PSA has limited specificity for prostate cancer detection, and its appropriate clinical application remains a topic of debate, it has been shown to correlate with cancer grade and some measures of tumour volume. We sought to replicate these findings and also establish the utility of PSA as a potential biomarker for prognostic indicators in patients with needle biopsies positive for prostate adenocarcinoma. Following clinical audit CoPath electronic archive search using keywords ‘prostate’ and ‘adenocarcinoma,’ anonymized reports from 43 clinical audit needle biopsies positive for prostate adenocarcinoma from 2015 through 2022 were reviewed. Data on primary and secondary tumour grade, histologic Gleason score, Grade group, tumour volume, perineural invasion and extraprostatic extension were reviewed with associated PSA levels. Patients with cancers that fell into Grade groups 1 and 2 (Gleason 3+3 and 3+4), had an average PSA level of 10.55 ng/ml, while those in higher Grade groups 3, 4 and 5 (Gleason 4+3, 4+4, 4+5, 5+4 and 5+5), had an average PSA of 26.09 ng/ml. Patients with higher tumour volume (> = 60% of biopsy tissue containing tumour) had an average PSA level of 22.98 ng/ml, while patients with lower tumour volume (<or = 40% of biopsy tissue containing tumour) had an average PSA level of 8.60 ng/ml. In patients with perineural invasion their average PSA level was 16.34 ng/ml, while those without had an average of 12.30 ng/ml. Similarly, patients with extraprostatic extension had an average PSA of 20.50 ng/ml, while those without had an average of 12.90 ng/ml.
Keywords: Prostate Cancer; Tumor Volume; Grade Groups; Perineural Invasion; Extraprostatic Extension
Citation: Paul H Hartel., et al. “Serum Prostate-Specific Antigen (PSA) Level is a Biomarker for Prostate Adenocarcinoma Grade, Tumour Volume and Histologic Prognostic Indicators”.Acta Scientific Medical Sciences 7.1 (2023): 60-63.
Copyright: © 2022 Paul H Hartel., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.